Scarica l'app Stockscreener
1.28
3.76%
-0.05
Dopo l'orario di chiusura:
1.34
0.06
+4.69%
Precedente Chiudi:
$1.33
Aprire:
$1.31
Volume 24 ore:
3.87M
Relative Volume:
1.38
Capitalizzazione di mercato:
$361.72M
Reddito:
$53.43M
Utile/perdita netta:
$-52.49M
Rapporto P/E:
-3.5665
EPS:
-0.3589
Flusso di cassa netto:
$-58.29M
1 W Prestazione:
-15.23%
1M Prestazione:
-25.58%
6M Prestazione:
+4.92%
1 anno Prestazione:
+121.03%
Intervallo 1D:
$1.26
$1.335
Intervallo di 1 settimana:
$1.17
$1.5562
Portata 52W:
$0.46
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Nome
Invivyd Inc
Settore
Industria
Telefono
(781) 819-0080
Indirizzo
209 CHURCH STREET, NEW HAVEN
Compare IVVD vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
1.28 | 361.72M | 53.43M | -52.49M | -58.29M | -0.3589 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-22 | Iniziato | BTIG Research | Buy |
| 2025-11-25 | Downgrade | D. Boral Capital | Buy → Hold |
| 2025-10-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-04-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-03-26 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Invivyd Inc Borsa (IVVD) Ultime notizie
IVVD Technical Analysis & Stock Price Forecast - Intellectia AI
Invivyd, Inc. (NASDAQ:IVVD) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Invivyd Inc. (IVVD) Stock Price Quote Today & Current Price Chart - Capital.com
Joel Greenblatt's Invivyd Inc(IVVD) Holding History - gurufocus.com
Invivyd Announces Presentation at the World Vaccine Congress Washington - The Manila Times
At vaccine congress, Invivyd says antibody drugs can track viral shifts - Stock Titan
Investment Recap: What makes Invivyd Inc stock attractive today2026 Short Interest & High Yield Equity Trading Tips - baoquankhu1.vn
Exploring Three High Growth Tech Stocks In The US Market - simplywall.st
Analysis Recap: What is the target price for Invivyd Inc stockTrade Signal Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
HC Wainwright & Co. Maintains Invivyd (IVVD) Buy Recommendation - MSN
Insider Buy: How liquid is Invivyd Inc stock2026 Breakouts & Breakdowns & Weekly Top Performers Watchlists - baoquankhu1.vn
Aug Gainers: What is the target price for Invivyd Inc stock2026 Gainers & Daily Momentum Trading Reports - baoquankhu1.vn
Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching (NASDAQ:IVVD) - Seeking Alpha
Inflation Data: Is Invivyd Inc exposed to currency risksWeekly Gains Report & AI Enhanced Trading Alerts - baoquankhu1.vn
Invivyd (IVVD) Q4 2025 Earnings Call Transcript - AOL.com
FY2027 Earnings Estimate for Invivyd Issued By HC Wainwright - MarketBeat
Invivyd Earnings Call Highlights Pivotal Trial Momentum - The Globe and Mail
Invivyd (NASDAQ:IVVD) Stock Price Up 6.3%Still a Buy? - MarketBeat
Invivyd appoints Michael Mina as chief medical officer - Investing.com Nigeria
Invivyd, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:IVVD) 2026-03-08 - Seeking Alpha
Invivyd, Inc. (NASDAQ:IVVD) Q4 2025 Earnings Call Transcript - Insider Monkey
Invivyd, Inc. (NASDAQ:IVVD) Receives Average Rating of "Hold" from Analysts - MarketBeat
Invivyd Q4 2025 slides: revenue surges 31%, pipeline advances By Investing.com - Investing.com Canada
Invivyd earnings beat by $0.11, revenue topped estimates - Investing.com Australia
Invivyd Q4 Earnings Call Highlights - MarketBeat
Michael Mina Appointed Chief Medical Officer at Invivyd - geneonline.com
Invivyd appoints Michael Mina as chief medical officer By Investing.com - Investing.com Australia
Invivyd Q4 2025 slides: revenue surges 31%, pipeline advances - Investing.com Nigeria
Invivyd Names Michael Mina Chief Medical Officer - Contract Pharma
Invivyd, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Invivyd Appoints Michael Mina, M.D., Ph.D. as Chief Medical Officer - citybiz
Earnings call transcript: Invivyd Q4 2025 shows robust growth and strategic expansion - Investing.com
Invivyd Advances VYD2311 With Key Phase 3 Alignments - TipRanks
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer - The Globe and Mail
Invivyd 2025 10-K: Revenue $53.4M, Net Loss $52.5M - TradingView
Invivyd FY revenue rises; operating expenses cut sharply - TradingView
Michael Mina named chief medical officer, Invivyd, Inc. announces - Traders Union
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates - The Manila Times
COVID testing voice Michael Mina now steering antibody drug effort - Stock Titan
Invivyd's Fourth Quarter 2025: Market Achievements Reflected in Valuation, Uneven Pipeline Risk - Bitget
An Overview of Invivyd's Earnings - Benzinga
Invivyd (IVVD) to Release Earnings on Thursday - MarketBeat
Invivyd Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Invivyd (IVVD): Post-Data Plunge, Cash Runway And Next Catalysts For US Traders - AD HOC NEWS
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
IVVD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 - The Manila Times
New Invivyd staff get options on 192,000 shares at $1.69 each - Stock Titan
Invivyd Inc Azioni (IVVD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):